BrainCheck

BrainCheck operates a digital platform for cognitive assessment and care planning used by clinicians in primary care, neurology, geriatrics, psychiatry, behavioral health, and academic research. The platform combines population analytics, screening, assessment, interpretation, care planning, and follow-up in a single workflow, and includes roughly 29-30 validated clinical evaluation tools such as screeners, functional assessments, and surveys. Its flagship and only FDA-registered Class II component, BrainCheck Assess, is a digital battery of about 15 minutes covering five cognitive domains — attention, memory, mental flexibility, processing speed, and executive function — using digitized versions of established neuropsychological tests including Trails A and B, immediate and delayed recognition, Digit-Symbol Substitution, and the Stroop Color and Word test. A shorter product, BrainCheck Screen, delivers a three-minute screen intended to establish medical necessity within annual wellness visit workflows and determine whether fuller assessment is warranted.

As a Class II device, BrainCheck Assess is subject to FDA audits and oversight, and the company maintains an FDA-compliant quality management system with regulated development, validation, and change-control processes. The company also reports HITRUST certification with ongoing audits, support for HIPAA-compliant workflows, and execution of Business Associate Agreements with covered entities. Results are positioned as decision support for clinician-led interpretation rather than a stand-alone diagnostic; the platform does not diagnose disease. Scoring is normed against a 5,000-patient normative database stratified by age and education, and the platform is supported by a real-world dataset of more than 450,000 patient assessments, with product releases roughly every two weeks.

BrainCheck's strategy is oriented toward value-based and risk-bearing care models, positioning standardized digital cognitive assessment as an entry point into structured cognitive care pathways alongside blood-based biomarkers and emerging therapies. Beyond software, the company partners with collaborative care organizations to operationalize cognitive care delivery in practices lacking the staffing or infrastructure to run comprehensive care workflows.

Business model

BrainCheck licenses its cognitive assessment and care planning platform to healthcare providers, practices, and health systems, with testing protocols customizable within the platform and results delivered into the electronic health record. Screening is positioned to establish medical necessity for subsequent reimbursable assessments, and the company also offers operational care-enablement partnerships with collaborative care organizations to run cognitive care workflows on behalf of practices.

Provider- and health-system-facing software sales, including a self-service sign-up tier for practices with fewer than 1,000 patients aged 65 and over, alongside enterprise deployments sold via demos and sales engagement. The company reported year-over-year revenue growth of three times in the year preceding its November 2021 Series B.

Traction

Used by more than 500 healthcare organizations nationwide as of February 2026, including 46 research hospitals, with more than 640,000 cognitive assessments and 14,000 care plans completed to date and more than 100,000 administrations of BrainCheck Assess in the preceding 12 months. The company website cites a real-world dataset of more than 450,000 patient assessments. In November 2021, over 400 neurology, primary care, and geriatrics practices used the product, and revenue had grown three times year over year.

Latest developments

In February 2026 BrainCheck announced an additional $13 million in Series A financing led by Next Coast Ventures with S3 Ventures and UPMC Enterprises, earmarked for deeper workflow integration, longitudinal monitoring, population-scale deployment, and AI-assisted clinical infrastructure for risk-bearing and value-based settings, plus partnerships with collaborative care organizations. On July 30, 2026 the company launched Population Analytics to support proactive cognitive care. Active research initiatives include a $157K Johns Hopkins A2 pilot grant for an AI scoring algorithm (02/2026-06/2027), a $213K University of Pennsylvania A2 pilot grant for the BrainCheck Connect AI companion (N=20 pilot in progress), a $500K NIA grant for an eConsult platform, blood-biomarker correlation work (p-Tau217, A\u03b242/A\u03b240, GFAP), a UPMC ADRC validation study, a 200-participant remote testing validation study, the EU PREDICTOM study (N=4,000), and a three-year Emory longitudinal study (N=270) launching Q3 2026. An updated scoring algorithm is slated to launch in 2026 following a 2025 normative database expansion of 1,382 participants.